DETAILED NOTES ON ABBV-744 BRD4 INHIBITOR MECHANISM OF ACTION

In Phase C, members will obtain ABBV-744 and oral navitoclax. In Phase D, participants will get ABBV-744 and ruxolitinib. Participants will get treatment until eventually ailment progression or maybe the participants are not able to tolerate the study drugs.For all move cytometry experiments, 10,000 cells for every replicate have been analyzed, and